Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience

R. Petrioli; G. Roviello; A. I. Fiaschi; L. Laera; Salvatora T. Miano; G. De Rubertis; G. Barbanti; V. Bianco; S. Brozzetti; E. Francini

doi:10.1007/s12032-015-0485-2

Back

Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience

Journal article

Peer reviewed

Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience

R. Petrioli, G. Roviello, A. I. Fiaschi, L. Laera, Salvatora T. Miano, G. De Rubertis, G. Barbanti, V. Bianco, S. Brozzetti and E. Francini

Medical oncology (Northwood, London, England), Vol.32(3), pp.52-7

03/2015

DOI: 10.1007/s12032-015-0485-2

PMID: 25636506

View Online

Abstract

The aim of this paper was to evaluate the activity and tolerability of weekly docetaxel (D) combined with weekly epirubicin (EPI) in patients with advanced castrate-resistant prostate cancer (CRPC) previously exposed to D and abiraterone acetate (AA). Locally advanced or metastatic CRPC patients with 0–2 performance status, who had progressed after D and AA therapy, were included in the study. Previous treatment with chemotherapy agent cabazitaxel was also admitted. Treatment consisted of D 30 mg/m 2 intravenously (i.v.) and EPI 30 mg/m 2 i.v., every week (D/EPI). Chemotherapy was administered until disease progression or unacceptable toxicity. In our institution, twenty-six patients received D/EPI: their median age was 72 years (range 59–83 years). Twenty-three (88.5 %) patients had bone metastases. A decrease in PSA levels ≥50 % was observed in seven patients (26.9 %, 95 % CI: 0.11–0.47); of these, five had achieved a ≥50 % PSA response during prior first-line D and six had achieved a PSA response during prior AA Among the subjects who were symptomatic at baseline, pain was reduced in nine patients (38.1 %) with a significant decrease in analgesic use. Median progression-free survival was 4.4 months (95 % CI, 3–5.2), and median overall survival was 10.7 months (95 % CI, 8.9–18.4). Treatment was well tolerated and no grade 4 toxicities were observed. Our findings suggest that weekly D/EPI is feasible and active in heavily pretreated advanced CRPC patients and seem to support the hypothesis that the addition of EPI to D may lead to overcome the resistance to D in a subgroup of patients.

Hematology

Internal Medicine

Medicine

Medicine & Public Health

Oncology

Original Paper

Pathology

Details

Title: Subtitle: Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience
Creators: R. Petrioli - University of Siena
G. Roviello - University of Siena
A. I. Fiaschi - University of Siena
L. Laera - University of Siena
Salvatora T. Miano - University of Siena
G. De Rubertis - University of Siena
G. Barbanti - University of Siena
V. Bianco - Policlinico Umberto I
S. Brozzetti - Policlinico Umberto I
E. Francini - Policlinico Umberto I
Resource Type: Journal article
Publication Details: Medical oncology (Northwood, London, England), Vol.32(3), pp.52-7
DOI: 10.1007/s12032-015-0485-2
PMID: 25636506
ISSN: 1357-0560
eISSN: 1559-131X
Publisher: Springer US
Language: English
Date published: 03/2015
Academic Unit: Internal Medicine
Record Identifier: 9985221145402771

Metrics

1 Record Views

15 Times Cited - Web of Science